Neurofibrosarcoma clinical trials
The registry lists 67 studies for Neurofibrosarcoma across more than 10 countries. 22 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-24.
Status
- Completed
- 24
- Recruiting
- 18
- Terminated
- 8
- Active, not recruiting
- 8
- Status unknown
- 3
- Enrolling by invitation
- 2
Phase
- Phase 2
- 42
- Phase 1
- 27
- Phase 3
- 3
Where
- United States
- 53
- Canada
- 5
- China
- 4
- Puerto Rico
- 2
- Japan
- 2
- France
- 2
Who runs them
National Cancer Institute (NCI) (14) · Memorial Sloan Kettering Cancer Center (4) · Sarcoma Alliance for Research through Collaboration (4) · Maria Sklodowska-Curie National Research Institute of Oncology (2) · OHSU Knight Cancer Institute (2) · Seattle Children's Hospital (2) · St. Jude Children's Research Hospital (2) · Tango Therapeutics, Inc. (2)
Studies
Recruiting first, then most recently updated. Showing 50 of 67 — search for more.
- Metarrestin (ML-246) in Subjects With Metastatic Solid TumorsRecruitingNCT04222413Phase 11 country
- DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical MarginsRecruitingNCT072980831 country
- Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid TumorsRecruitingNCT05732831Phase 1/23 countries
- Phase 1 Study of MRTX1719 in Solid Tumors With MTAP DeletionRecruitingNCT05245500Phase 11 country
- Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)RecruitingNCT062222031 country
- Neurofibromatosis Type 1 Tumor Early Detection StudyEnrolling by invitationNCT065158601 country
- Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for SarcomasRecruitingNCT05253131Phase 21 country
- SPEARHEAD-3 Pediatric StudyRecruitingNCT05642455Phase 1/21 country
- Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath TumorRecruitingNCT07549022Phase 1/21 country
- Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath TumorNot yet recruitingNCT07743554Phase 2
- NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)RecruitingNCT06239272Phase 1/21 country
- Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNSTRecruitingNCT06735820Phase 1/21 country
- A Study of DEG6498 in Participants With Solid TumorsRecruitingNCT07244835Phase 11 country
- B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)RecruitingNCT04897321Phase 11 country
- A Study of Selinexor in People With Wilms Tumors and Other Solid TumorsRecruitingNCT05985161Phase 21 country
- Agnostic Therapy in Rare Solid TumorsRecruitingNCT06638931Phase 21 country
- Multi-Institutional Registry for Malignant Peripheral Nerve Sheath TumorsRecruitingNCT031410215 countries
- BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of BreastAvailableNCT040912951 country
- A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)RecruitingNCT04872543Phase 21 country
- IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)RecruitingNCT06849986Phase 21 country
- Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMAEnrolling by invitationNCT06603987Phase 1/21 country
- MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue SarcomaRecruitingNCT06277154Phase 21 country
- Natural History Study of Patients With Neurofibromatosis Type IActive, not recruitingNCT009241961 country
- Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1CompletedNCT02211768Phase 11 country
- Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by SurgeryCompletedNCT02180867Phase 2/33 countries
- Nivolumab and Ipilimumab in Treating Patients With Rare TumorsActive, not recruitingNCT02834013Phase 22 countries
- APX005M and Doxorubicin in Advanced SarcomaCompletedNCT03719430Phase 21 country
- Tazemetostat in Malignant Peripheral Nerve Sheath TumorsActive, not recruitingNCT04917042Phase 21 country
- SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath TumorsCompletedNCT03433183Phase 21 country
- B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young AdultsActive, not recruitingNCT04483778Phase 11 country
- Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid TumorsTerminatedNCT05275478Phase 1/22 countries
- Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue SarcomaActive, not recruitingNCT04420975Phase 11 country
- Multi-parametric Biomarker Development to Predict Malignant Conversion in Patients With Neurofibromatosis Type 1Active, not recruitingNCT056775941 country
- EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young AdultsActive, not recruitingNCT03618381Phase 11 country
- A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid TumorsActive, not recruitingNCT03611868Phase 1/22 countries
- Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young AdultsTerminatedNCT04530487Phase 21 country
- A Study of Different Dosing Schedules of Selinexor in Sarcoma PatientsCompletedNCT04811196Phase 11 country
- PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath TumorsTerminatedNCT02584647Phase 1/21 country
- Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by SurgeryCompletedNCT02700230Phase 11 country
- Incidence of Malignant Peripheral Nerve Sheath Tumor (MPNST) Development in Participants With Neurofibromatosis Type 1 (NF1) Receiving and Not Receiving Medical Therapies Directed at Plexiform Neurofibromas (PN)CompletedNCT047742891 country
- A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I NeurofibromatosisTerminatedNCT05011019Phase 1/21 country
- Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue SarcomaCompletedNCT02584309Phase 21 country
- Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by SurgeryCompletedNCT03009201Phase 11 country
- Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic SarcomaTerminatedNCT02601209Phase 1/21 country
- Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue SarcomaCompletedNCT00346164Phase 35 countries
- Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue SarcomaCompletedNCT01532687Phase 21 country
- A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative SurgeryTerminatedNCT02691026Phase 21 country
- Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue SarcomasStatus unknownNCT03989596Phase 21 country
- Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk WallStatus unknownNCT03651375Phase 21 country
- Selinexor in Combination With Ixazomib for the Treatment of Advanced SarcomaWithdrawnNCT03880123Phase 11 country